New York, NY – For decades, the role of regulatory T (Treg) cells in cancer has been a perplexing paradox, particularly in colorectal cancer. While these immune cells, known for their ability to suppress the immune system, are typically associated with worse outcomes in most solid tumors, their presence in colorectal cancer (CRC) has bafflingly correlated with improved patient survival. This long-standing enigma, which has hindered the development of effective immunotherapies for a significant portion of CRC patients, has now been unraveled by a groundbreaking study from the Sloan Kettering Institute at Memorial Sloan Kettering Cancer Center (MSK).
Published in the prestigious scientific journal Immunity, the research reveals a critical distinction: not all Treg cells are created equal. Instead of a monolithic entity uniformly dampening anti-cancer immunity, the study identifies two distinct subtypes of Treg cells within colorectal tumors, each playing an opposing role in disease progression. This pivotal discovery not only explains the unique immune landscape of colorectal cancer but also opens promising new avenues for precision immunotherapy, particularly for the most common forms of the disease that currently respond poorly to existing treatments. The implications may also extend to other cancers arising in "barrier tissues" like the skin, mouth, throat, and stomach.
"Instead of the regulatory T cells promoting tumor growth, as they do in most cancers, in colorectal cancer we discovered there are actually two distinct subtypes of Treg cells that play opposing roles — one restrains tumor growth, while the other fuels it," explains Dr. Alexander Rudensky, PhD, co-senior author of the study and chair of the Immunology Program at MSK. "It’s these beneficial Treg cells that make the difference, and this underscores the need for selective approaches."
The Enigma of Colorectal Cancer: A Long-Standing Immune Puzzle
For years, the scientific community grappled with the contradictory behavior of Treg cells in colorectal cancer. In the vast majority of solid tumors, including melanoma, lung, and kidney cancers, an abundance of Treg cells is a clear red flag, signaling a compromised immune response against the malignancy. These cells act as powerful "brakes" on the immune system, preventing it from launching a full-scale attack on cancerous cells. This immunosuppressive function makes them a prime target for therapies aimed at unleashing the body’s natural defenses.
However, colorectal cancer stood as a stark exception. Clinical observations repeatedly showed that CRC patients whose tumors harbored higher numbers of Treg cells often experienced longer survival times. This counterintuitive finding challenged established immunological paradigms and presented a significant hurdle for researchers attempting to develop universal immunotherapy strategies. Without understanding why Tregs behaved differently in CRC, targeting them carried the risk of inadvertently harming beneficial immune responses.
A Legacy of Immunological Insight: Two Decades of Treg Research
The current breakthrough is built upon more than two decades of foundational research led by Dr. Alexander Rudensky, a world-renowned expert in regulatory T cell biology. His pioneering work at MSK has been instrumental in establishing the fundamental role of Treg cells in maintaining "immune tolerance." This vital process allows the immune system to differentiate between harmful pathogens and harmless self-components, beneficial microbes, or everyday environmental factors, thereby preventing autoimmune diseases and allergic reactions.
Over the years, Dr. Rudensky’s laboratory has meticulously uncovered the intricate mechanisms governing Treg cell development, function, and their complex interactions within various physiological and pathological contexts, including cancer. This deep understanding of Treg biology provided the essential framework for investigating their nuanced roles in specific tumor microenvironments, ultimately leading to the revelation that would resolve the colorectal cancer paradox.
The multi-institutional and highly collaborative study was led by first authors Dr. Xiao Huang, PhD, a postdoctoral researcher in the Rudensky Lab; Dr. Dan Feng, MD, PhD, a former MSK Medical Oncology fellow now at the Icahn School of Medicine at Mount Sinai; and Dr. Sneha Mitra, PhD, a postdoctoral researcher in the lab of computational biologist Dr. Christina Leslie, PhD, who served as the study’s other senior author. Their combined expertise in immunology, oncology, and computational biology proved critical in dissecting the complex data and arriving at these transformative conclusions.
Unraveling the Complexity: Focus on Common Colorectal Cancer
Colorectal cancer remains a formidable health challenge, ranking as the second leading cause of cancer-related death when statistics for men and women are combined, according to the American Cancer Society. A significant hurdle in its treatment is the heterogeneity of the disease itself.
The MSK researchers specifically focused on the most common form of colorectal cancer, which accounts for approximately 80% to 85% of all CRC cases. These tumors are characterized as microsatellite stable (MSS) with proficient mismatch repair (MMRp), meaning their DNA is relatively stable. Crucially, this subtype of CRC typically exhibits a poor response to checkpoint inhibitor immunotherapies – a class of drugs that have revolutionized the treatment of many other cancers by "releasing the brakes" on the immune system.
Earlier research at MSK and elsewhere demonstrated the remarkable efficacy of checkpoint inhibitors against the opposite tumor type: cancers with high microsatellite instability (MSI-H) and mismatch repair deficiency (MMRd). For these patients, immunotherapy alone can often lead to durable responses, frequently allowing them to avoid more invasive treatments like surgery, chemotherapy, and radiation. The lack of effective immunotherapy options for the vast majority of MSS CRC patients underscored the urgent need for a deeper understanding of their unique immune landscape.
Two Sides of the Same Coin: The Opposing Roles of Treg Subtypes
To decipher what made common colorectal cancers different, the research team utilized a sophisticated mouse model developed at MSK that faithfully recapitulates the genetic alterations, tumor behavior, and immune environment observed in human colorectal tumors. This robust model allowed for precise manipulation and observation of immune cell populations within the tumor microenvironment.
Their meticulous investigations led to a pivotal discovery: tumor-associated Treg cells are not a homogenous population but rather comprise two distinct main groups. The key differentiator was the production of a specific signaling molecule, or cytokine, called interleukin-10 (IL-10). One group of Treg cells produced IL-10, while the other did not.
Through a series of detailed experiments involving the selective removal of each group, the researchers uncovered profound and opposing effects on tumor growth.
1. The Beneficial, Tumor-Restraining Treg Subtype (IL-10-positive):
These Treg cells were found to actively help slow tumor growth. Their mechanism involved reducing the activity of Th17 cells, another type of immune cell known to produce interleukin-17 (IL-17). IL-17 acts as a growth signal for tumors, promoting their proliferation and survival. By suppressing Th17 cells and thus IL-17 production, IL-10-positive Treg cells effectively deprived tumors of a critical growth stimulus. Importantly, these protective Treg cells were more commonly found in the healthy tissue surrounding the tumor, suggesting a role in maintaining tissue homeostasis and preventing aberrant inflammation that could otherwise fuel cancer. When these IL-10-positive Treg cells were experimentally removed, tumors grew more quickly, unequivocally demonstrating their beneficial role.
2. The Harmful, Tumor-Fueling Treg Subtype (IL-10-negative):
In stark contrast, the IL-10-negative Treg cells exhibited the opposite effect. These cells were potent suppressors of powerful immune defenders, particularly CD8+ T cells, which are renowned for their direct cancer-fighting abilities. By dampening the activity of CD8+ T cells, these harmful Tregs created an immunosuppressive environment within the tumor, allowing cancer cells to evade immune surveillance and proliferate unchecked. This detrimental subtype was predominantly located inside the tumor itself, strategically positioned to neutralize anti-tumor immune responses. When these IL-10-negative Treg cells were selectively eliminated in experiments, tumors significantly shrank, confirming their role as drivers of tumor progression.
Human Validation: From Lab Bench to Patient Data
To ensure the relevance of their findings to human disease, the MSK team rigorously validated their results using tumor samples obtained from actual colorectal cancer patients. Consistent with their mouse model observations, they successfully identified two distinct populations of IL-10-positive and IL-10-negative Treg cells within these human samples.
Further reinforcing the clinical significance of their discovery, the researchers analyzed outcomes for over 100 colorectal cancer patients. The results were compelling: patients whose tumors contained higher levels of the beneficial IL-10-positive Treg cells exhibited significantly longer survival times. Conversely, patients whose tumors harbored a greater proportion of the harmful IL-10-negative Treg cells experienced poorer clinical outcomes.
"This research shows how important these positive cells are," says Dr. Huang, emphasizing the clinical relevance of the findings. "And it highlights the need to develop therapies that can selectively eliminate the harmful Tregs while preserving the helpful ones."
Implications: Revolutionizing Colorectal Cancer Immunotherapy
The findings from this landmark study suggest a transformative path forward for improving treatment strategies for the majority of colorectal cancer patients, particularly those with MSS CRC who currently lack effective immunotherapy options.
Targeting CCR8: A Precision Strike Against Harmful Tregs
A critical aspect of the discovery relates to a specific molecular marker. The researchers found that the harmful IL-10-negative Treg cells express high levels of a protein called CCR8. These are precisely the cells that suppress the immune response and are predominantly found within the tumor microenvironment. This molecular signature provides a highly specific target for therapeutic intervention.
Intriguingly, earlier work from Dr. Rudensky’s lab, spearheaded by breast cancer surgeon Dr. George Plitas, MD, had already identified CCR8 as being highly expressed on tumor Treg cells in breast cancer and numerous other human cancers. That seminal research had suggested the potential for developing antibodies that could selectively deplete these harmful CCR8-expressing Treg cells. The idea was to unleash the immune system’s full power against tumors while leaving the beneficial, non-CCR8-expressing Treg cells intact, thereby minimizing potential off-target effects or autoimmune complications.
"This idea of using CCR8-depleting antibodies, which was pioneered at MSK, is the main target of global efforts to bring regulatory T cell-based immunotherapy to the clinic," Dr. Rudensky affirms, underscoring the broad impact and recognition of this innovative strategy.
Indeed, this therapeutic approach is not merely theoretical; multiple clinical trials are currently underway at MSK and other leading institutions worldwide. These trials are testing CCR8-targeting antibodies both as standalone treatments and in combination with existing immunotherapies, aiming to enhance anti-tumor responses. The new study strongly strengthens the rationale for applying this targeted strategy specifically in colorectal cancer, and potentially far beyond.
Beyond Colorectal Cancer: A Universal Mechanism in Barrier Tissues?
The researchers also broadened their scope, examining a comprehensive dataset of T cells derived from 16 different cancer types to ascertain whether similar immune patterns existed elsewhere. Their analysis revealed intriguing parallels: similar divisions between IL-10-positive and IL-10-negative Treg cells were identified in several cancers affecting the skin and the lining of the mouth, throat, and stomach – tissues collectively known as "barrier tissues."
"What these tissues have in common is that immune cells play a critical role in constantly defending and repairing them as they’re exposed to microbes and environmental stresses," explains Dr. Mitra, who led the extensive data analysis and is co-mentored by Dr. Leslie and Dr. Rudensky. This shared characteristic suggests a conserved evolutionary mechanism where different Treg subsets might be required to balance immune protection with immune tolerance in tissues constantly exposed to the external environment.
This finding has profound implications, suggesting that therapeutic strategies designed to remove IL-10-negative Treg cells in colorectal cancer might also prove effective against these other cancers that originate in barrier tissues, significantly expanding the potential reach of this precision immunotherapy approach.
Navigating Metastasis: A Nuanced Approach to Advanced Disease
While the study offers immense hope for primary colorectal tumors, it also provides crucial insights into the complexities of metastatic disease. When the researchers examined colorectal cancer that had spread to the liver – a common site for CRC metastasis – they observed a distinctly different immune pattern.
In these metastatic liver tumors, the harmful IL-10-negative Treg cells dramatically outnumbered the helpful IL-10-positive cells. This shift in the Treg subtype balance indicated a predominantly immunosuppressive environment. Unlike in primary tumors, where selective targeting is paramount, the removal of all Treg cells in this metastatic context actually caused the tumors to shrink.
This result highlights a critical principle in oncology: treatment strategies must be highly nuanced, accounting for both the specific tissue involved and, crucially, the stage of the disease. What works for a primary tumor may need to be adapted or even reversed for metastatic lesions, underscoring the ongoing challenge and complexity of treating advanced cancers.
The Future Landscape of Precision Immunotherapy
This landmark study from Memorial Sloan Kettering Cancer Center represents a significant leap forward in understanding the intricate interplay between the immune system and cancer. By dissecting the heterogeneous nature of regulatory T cells, MSK researchers have not only resolved a long-standing paradox in colorectal cancer but have also unveiled a promising, highly targeted approach for immunotherapy.
The ability to selectively eliminate harmful Treg subtypes while preserving beneficial ones heralds a new era of precision immunotherapy, moving beyond broad immune activation to exquisitely tailored interventions. As clinical trials progress with CCR8-depleting antibodies, the scientific community and patients alike look forward to the potential for these discoveries to translate into improved outcomes and a brighter future for those battling colorectal cancer and potentially a range of other challenging malignancies. The journey from unraveling a biological mystery to developing life-saving therapies is long and arduous, but this research marks a pivotal moment, illuminating a clearer path forward.
Authors, Funding, and Disclosures:
Additional authors of the study include Emma Andretta, Nima Hooshdaran, Aazam Ghelani, Eric Wang, Joe Frost, Victoria Lawless, Aparna Vancheswaran, Qingwen Jiang, Cheryl Mai, and Karuna Ganesh.
The Integrated Genomics Operation and the Single Cell Research Initiative at MSK played key roles in facilitating the research.
Funding for this groundbreaking work was generously provided by the National Cancer Institute (P30 CA008748, U54 CA274492, T32 CA009512), the National Institute of Allergy and Infectious Diseases (AI034206), the Ludwig Center for Cancer Immunotherapy at MSK, the Howard Hughes Medical Institute, the Cancer Research Institute, and a Marie-Josée Kravis Fellowship in Quantitative Biology.
Dr. Rudensky serves on scientific advisory boards and holds equity in Sonoma Biotherapeutics, RAPT Therapeutics, Coherus Oncology, Santa Ana Bio, Odyssey Therapeutics, and Nilo Therapeutics. He is also a scientific advisory board member of Amgen, BioInvent, and Vedanta Biosciences, has consulted for AbbVie, and serves as an editor of the Journal of Experimental Medicine and an editorial advisor to Immunity.
Dr. Rudensky and Dr. Plitas are inventors on patents and patent applications held by MSK related to CCR8-based therapeutic depletion of tumoral Treg cells and novel antibodies against CCR8.
About the Author
